A Phase 1b/2 Study of Ramucirumab in Combination With LY2875358 in Patients With Advanced Cancer
Active, no longer recruiting
Phase of Trial: Phase I/II
Latest Information Update: 08 Feb 2018
At a glance
- Drugs Emibetuzumab (Primary) ; Ramucirumab
- Indications Adenocarcinoma; Gastric cancer; Liver cancer; Oesophageal cancer; Renal cell carcinoma; Solid tumours
- Focus Adverse reactions; Therapeutic Use
- Sponsors Eli Lilly
- 01 Feb 2018 Planned End Date changed from 1 Dec 2017 to 1 Jun 2018.
- 18 Jul 2017 Status changed from recruiting to active, no longer recruiting.
- 20 May 2017 Planned End Date changed from 1 Oct 2017 to 1 Dec 2017.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History